TriSalus Life Sciences, Inc. (TLSI) Stock
Healthcare · Medical Devices · Member of Other US Stocks
TriSalus Life Sciences, Inc. (TLSI) closed at USD 3.90 on 2026-10-14, a change of -20.6 % over the past year, with a market capitalization of USD 240.14M.
TriSalus Life Sciences, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 3.90 |
| 2026-10-13 | 4.00 |
| 2026-10-12 | 4.14 |
| 2026-10-09 | 4.06 |
| 2026-10-08 | 4.13 |
| 2026-10-07 | 4.25 |
| 2026-10-06 | 4.27 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
TriSalus Life Sciences, Inc. key figures
- Previous close
- USD 3.90 (2026-10-14)
- 1-year change
- -20.6 %
- Market cap
- USD 240.14M
- Enterprise value
- USD 228.28M
- P/E ratio (trailing)
- -3.31
- P/E ratio (forward)
- -15.60
- EPS (trailing)
- -1.18
- EPS (forward)
- -0.25
- PEG ratio
- n/a
- Price to book
- 36.45
- Revenue growth
- 1.7 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 7.57
- Employees
- 102
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for TriSalus Life Sciences, Inc. and compare it with other stocks.
Analyze TLSIAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell TriSalus Life Sciences, Inc. shares.